Mostrar o rexistro simple do ítem

dc.contributor.authorAbalo Lojo, José Manuel *
dc.contributor.authorVázquez Ferreiro, Pedro*
dc.contributor.authorAsorey, M.K.*
dc.contributor.authorEstévez Colmenero, Aida*
dc.contributor.authorGonzález García, Francisco *
dc.date.accessioned2025-09-09T12:42:06Z
dc.date.available2025-09-09T12:42:06Z
dc.date.issued2023
dc.identifier.citationAbalo-Lojo JM, Ferreiro PV, Asorey MK, Colmenero AE, Gonzalez F. Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment. Turkish Journal of Ophthalmology. 2023;53(1):8-12.
dc.identifier.issn2149-8709
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/640d5f7cf0c92964f8440c9d
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21618
dc.description.abstractObjectives: To report that the periorbital changes induced by prostaglandin analogue (PGA) eye drops are partially reversible after discontinuing treatment. Materials and Methods: Nine patients with prostaglandin-associated periorbitopathy seen in a referral oculoplastic practice were included in this study, eight with unilateral glaucoma and one with bilateral open-angle glaucoma. All of them had been treated with topical PGA for at least one year, before the treatment was discontinued for cosmetic reasons. Results: In all cases, there were evident periocular differences between the treated eye and the fellow eye, consisting mainly of deepening of the upper eyelid sulcus and eyelid fat pad reduction. One year after discontinuing the PGA eye drops, improvement of these features was observed. Conclusion: Clinicians and patients should be aware of the side effects of topical PGA therapy on periorbital tissues, and that these side effects can partially regress after discontinuation of the medication.
dc.description.sponsorshipThis work was partially supported by the ISCIII (RETICS, Oftared, RD16/0008/003), Xunta de Galicia (Centro Singular de Investigacion, 2019-2022), and the European Union (European Regional Development Fund-ERDF).
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHumans *
dc.subject.meshGlaucoma, Open-Angle *
dc.subject.meshEyelids *
dc.subject.meshGlaucoma *
dc.subject.meshOphthalmic Solutions *
dc.subject.meshProstaglandins *
dc.titleImprovement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment
dc.typeArtigo
dc.authorsophosAbalo-Lojo, J.M.; Ferreiro, P.V.; Asorey, M.K.; Colmenero, A.E.; Gonzalez, F.
dc.identifier.doi10.4274/tjo.galenos.2022.24365
dc.identifier.sophos640d5f7cf0c92964f8440c9d
dc.issue.number1
dc.journal.titleTurkish Journal of Ophthalmology*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Oftalmoloxía
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario A Coruña::Oftalmoloxía
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Oftalmoloxía
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Oftalmoloxía
dc.page.initial8
dc.page.final12
dc.relation.projectIDISCIII (RETICS) [RD16/0008/003]
dc.relation.projectIDXunta de Galicia
dc.relation.projectIDEuropean Union (European Regional Development Fund-ERDF)
dc.relation.publisherversionhttps://doi.org/10.4274/tjo.galenos.2022.24365
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS Santiago
dc.subject.keywordCHUS
dc.subject.keywordAS A Coruña
dc.subject.keywordCHUAC
dc.subject.keywordAS Santiago
dc.subject.keywordCHUS
dc.subject.keywordAS Santiago
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number53


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Attribution 4.0 International (CC BY 4.0)
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAttribution 4.0 International (CC BY 4.0)